Tomasz Wróbel

机构：University of Wrocław, Wroclaw Medical University · ORCID：0000-0002-6612-3535

发表论文 449 篇 · 总被引 5132 次 · h-index 33

代表论文

Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2025 · Journal of Clinical Oncology · 被引 21)
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2025 · Journal of Clinical Oncology · 被引 14)
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial (2025 · The Lancet Haematology · 被引 6)
Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL – real-life data analysis of the Polish Adult leukemia group (2025 · Leukemia & lymphoma/Leukemia and lymphoma · 被引 4)
Prevalence of Hidradenitis Suppurativa in Poland (2025 · Dermatology · 被引 4)
Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). (2025 · Journal of Clinical Oncology · 被引 4)